来自城市和农村地区的生殖细胞癌患者的生存率没有差异
Dennis Hoch1, Simon Helnwein1, Davide Adrizzone2
1Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland.
Oncology research and treatment
|August 13, 2023
概括
这项研究发现,患有生殖细胞癌症 (GCC) 的男性,无论其居住地点如何,都表现出色. 在城市和农村地区,GCC患者的治疗成功率相似,显示他们均可获得高水平的护理.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 公共卫生 公共卫生
背景情况:
- 在大多数男性中,生殖细胞癌 (GCC) 是高度可治愈的.
- 之前的研究表明,与城市同行相比,GCC农村患者的治疗结果较差.
- 这种差异可能表明获得专门癌症护理的机会不平等.
研究的目的:
- 调查住宅位置是否会影响生殖细胞癌 (GCC) 患者的治疗结果.
- 为了比较来自瑞士城市,郊区和农村地区的患者之间的结果.
- 评估在不同住宅地区获得高水平瘤护理的机会.
主要方法:
- 在两个瑞士大学医院 (2010-2020年) 接受治疗的海湾医疗中心患者的回顾性图表审查.
- 数据抽象包括患者表现,诊断,治疗和结果.
- 根据瑞士联邦统计局的住宅区分类.
主要成果:
- 在城市和农村患者之间没有观察到初始呈现,复发率或治疗反应的显著差异.
- 所有住宅区的无进展生存率 (PFS) 和整体生存率 (OS) 是可比的.
- 在临床I期患者中,三年PFS为78%;五年OS为98%.
结论:
- 对于GCC患者来说,无论居住地点如何,都取得了优异的治疗结果.
- 这表明在城市和农村环境中均可获得高水平的瘤护理.
- 这些发现挑战了之前关于基于地理位置的结果差异的报告.
相关概念视频
Cancer Survival Analysis
384
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
384
Comparing the Survival Analysis of Two or More Groups
223
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
223
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancers Originate from Somatic Mutations in a Single Cell
12.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K


